Clovis Oncology is on a Mission to Advance the Fight Against Cancer
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Development Programs Are Focused on Providing the Right Drug, to the Right Patient at the Right Time
Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.